ABOUT US
QUALITY OF LIFE WITH A CHRONIC INFLAMMATORY DISEASE
Lipum AB (publ) is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases. The lead candidate drug (SOL-116) is a fully humanized antibody designed to give safer and more efficacious therapy by blocking a previously overlooked target molecule of the immune system.
Supported by solid pre-clinical data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis Lipum is exploring a range of other diseases with a high unmet medical need. We intend to show clinical proof of concept for SOL-116. This will enable a long-term sustainable business model through strategic partnerships.
Based in Umeå, an excellent life science cluster in Sweden, Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.
The company’s share (LIPUM) is traded on the Nasdaq First North Growth Market in Stockholm.
CURRENT PRESENTATIONS
BioStock Investor Meeting: Einar Pontén presents Lipum and more about the way forward.
September 29, 2022
Einar Pontén presents Lipum at BioStock Life Science Spring Summit.
Time: 3:28:00 | June 8, 2022
Einar Pontén in Focus interview at Redeye Growth Day.
June 2, 2022
Einar Pontén presents Lipum at Naventus Life Science Summit.
September 2021
Biostock interviews Einar Pontén, CEO Lipum
September 2021
Lennart Lundberg Joins Lipum’s Scientific Advisory Board.
Read more »
Watch our CEO Einar Pontén present Lipum at the spring edition of BioStock Life Science Summit.
May 2021